Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease
Authors:
- 1 March 2010
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 70 (5) , 513-528
Abstract
Current treatment options for Alzheimer’s disease (AD) exert only a shortlived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring auto-antibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Ab. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.Keywords
This publication has 106 references indexed in Scilit:
- APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasksNeuroscience & Biobehavioral Reviews, 2010
- Regulation of Fcγ receptors and immunoglobulin G-mediated phagocytosis in mouse microgliaNeuroscience Letters, 2009
- A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brainActa Neuropathologica, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences, 2008
- Active and Passive Immunotherapy for Neurodegenerative DisordersAnnual Review of Neuroscience, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjectsNeuroscience Letters, 2006
- Autoantibodies to alpha‐synuclein in inherited Parkinson’s diseaseJournal of Neurochemistry, 2006
- Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjectsNeuroscience Letters, 2004
- The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissuesClinical Immunology and Immunopathology, 1992